SRRK — Scholar Rock Holding Corporation

Scholar Rock Holding Corporation (SRRK) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Operating Expenses: Q4 2025 operating expenses were $91.9 million, including $19.4 million in non-cash stock-based compensation. Excluding this, operating expenses were $72.5 million. For the full year, operating expenses totaled $384.6 million ($309 million excluding stock-based compensation).
• Cash Position: Ended 2025 with $368 million in cash and cash equivalents, bolstered by $60.4 million from warrant exercises.
• New Debt Facility: Secured a new debt facility of up to $550 million, with $100 million immediately available to repay prior debts, and additional funds contingent on FDA approval of their lead product, upitigramab.

2. Strategic Updates and Business Highlights:

• Product Development: The company is focused on resubmitting the Biologics License Application (BLA) for upitigramab for spinal muscular atrophy (SMA) following a successful FDA reinspection of the Catalent facility. They expect to resubmit in 2026.
• Regulatory Engagement: Positive interactions with the FDA, including a recent meeting where no additional requests were made regarding the remediation plan for the manufacturing facility.
• Commercial Readiness: Preparations for the U.S. launch of upitigramab are underway, with a focus on educating prescribers and establishing a patient access support program. Launch in Europe is also planned for mid-2026.
• Pipeline Expansion: Advancements in their anti-myostatin pipeline, including ongoing studies for various neuromuscular diseases, with a Phase 2 study for facioscapulohumeral muscular dystrophy (FSHD) set to begin later this year.

3. Forward Guidance and Outlook:

• BLA Resubmission and Launch: The company reaffirms guidance for BLA resubmission and U.S. launch of upitigramab in 2026, contingent on successful FDA reinspection.
• European Approval: Anticipated decision from the European Medicines Agency (EMA) for the marketing authorization application (MAA) in mid-2026.
• Financial Strategy: Focused on maintaining a tight financial plan while investing in commercial readiness and R&D to support long-term growth.

4. Bad News, Challenges, or Points of Concern:

• Regulatory Risks: The timeline for resubmission and approval is dependent on the successful reinspection of the Catalent facility, which poses a risk if issues arise.
• Market Competition: The SMA treatment landscape is competitive, and while SRRK aims to be the first muscle-targeted therapy, they face pressure from existing SMN-targeted therapies.
• Payer Access: Initial access to the market may be hindered by reimbursement challenges, particularly with Medicaid and other payers that may take time to approve coverage.

5. Notable Q&A Insights:

• FDA Reinspection: The FDA has shown a high level of engagement and urgency regarding the reinspection of the Catalent facility, which is critical for the BLA resubmission.
• Class 2 Submission: There is a possibility that the BLA resubmission could be classified as Class 2, which typically involves a six-month review, but there are precedents for faster approvals.
• Payer Readiness: The company is actively engaging with payers and tracking readiness indicators, noting that while there is robust demand for upitigramab, initial access may face hurdles.
• Functional Improvement in Trials: For the upcoming FSHD study, the primary endpoint will focus on muscle volume, but functional endpoints will also be included to assess the drug's impact on muscle function.

This summary captures the essential financial metrics, strategic initiatives, forward-looking statements, and potential challenges Scholar Rock faces as it progresses toward the launch of its key product and expands its pipeline.